RT Journal Article
SR Electronic
T1 Improvement in RAID questionnaire results in patients with rheumatoid arthritis treated with advanced therapies
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2021-003084
DO 10.1136/ejhpharm-2021-003084
A1 Andrea Rodríguez Esquíroz
A1 Amaya Arrondo Velasco
A1 Amaia Egüés Lugea
A1 Maite Sarobe Carricas
YR 2022
UL http://ejhp.bmj.com/content/early/2022/02/27/ejhpharm-2021-003084.abstract
AB Objectives To analyse the changes in patient-reported outcomes after starting advanced antirheumatic treatment.Methods The study included all patients who started self-administered biological or targeted synthetic treatments for rheumatoid arthritis between February and November 2020. The patients were given the RAID quality of life questionnaire to complete before starting the treatment and after 4 months. Univariate and multivariate analyses were performed to determine the association between patients' clinical and sociodemographic characteristics and quality of life improvement. The level of significance was set at 0.05.Results Forty-six patients were included. Their ratings in the RAID questionnaire were improved after 4 months of treatment, both in the final overall total, which improved by 1.63±2.29 points, and in the different subtopics of the questionnaire (range 0–10). Pain was the domain that improved the most (2.33±2.82 points), followed by functional disability (2.15±2.51) and physical well-being (1.96±3.18). The improvement was statistically significant in all domains except the sleep score, which showed no statistically significant difference between the two time points analysed.Conclusions Advanced antirheumatic treatment improves the quality of life of patients after 4 months of treatment.All data relevant to the study are included in the article or uploaded as supplementary information.